Welcome to our dedicated page for Tecogen SEC filings (Ticker: TGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Tecogen’s disclosures usually means wading through technical CHP diagrams and detailed emissions data. Investors want the revenue split between product sales and long-term service, or need to confirm when executives file Form 4 insider transactions before major project wins. This page maps every SEC release to the exact question you are asking—whether it’s backlog growth or R&D spending—so you no longer have to hunt through dense footnotes.
Type a phrase like “Tecogen quarterly earnings report 10-Q filing” or “Tecogen proxy statement executive compensation” and Stock Titan returns the document plus an AI-powered summary that highlights segment margins, new clean-energy incentives, and board pay packages. Real-time alerts push Tecogen Form 4 insider transactions the moment they hit EDGAR, letting you track executive stock moves without refreshing your browser. Need context? Our expert engine links related 8-Ks, turning “Tecogen 8-K material events explained” into a concise timeline of project awards, financing rounds, or patent milestones.
Because Tecogen’s business blends equipment sales with recurring service revenue, understanding cash-flow nuances is critical. Our coverage spans every form—from the “Tecogen annual report 10-K simplified” that dissects backlog trends, to bite-size analytics for each “Tecogen earnings report filing analysis.” Use AI plain-language explanations to compare quarter-over-quarter growth, monitor compliance with clean-air regulations, and flag subsidy disclosures. In short, this hub is your fastest route to understanding Tecogen SEC documents with AI—all filings, all the time, always current.
Tecogen Inc. (TGEN) Form 4 filing: Chief Accounting Officer Roger P. Deschenes reported new equity awards dated 07/24/2025.
- Restricted stock: 17,964 common shares awarded at $0 cost; direct holdings rise to 42,962 shares.
- Stock options: 12,063 options granted with a $8.35 exercise price, expiring 07/24/2035; option balance increases to 152,063.
The awards vest 25% annually, providing long-term retention incentives and aligning the CAO’s interests with shareholders. No shares were sold or disposed of.
Form 4 – Tecogen Inc. (TGEN)
- Reporting person: Susan B. Hirsch, Director.
- Transaction date: 07/24/2025.
- Instrument: Stock Option (right to buy) covering 25,000 common shares at an exercise price of $8.35.
- Vesting: 25 % per year; first exercisable 07/24/2026; expiration 07/24/2035.
- Post-transaction holdings: Hirsch now directly holds 150,000 derivative securities (options).
No non-derivative (common stock) transactions were reported. The filing reflects a routine option grant to a board member and does not disclose cash compensation, sale activity, or changes in direct share ownership.
Form 4 filing for Tecogen Inc. (TGEN) discloses that director Ahmed Ghoniem received a new equity award on 24 Jul 2025.
- Security: Non-qualified stock option granting the right to purchase 25,000 common shares.
- Exercise price: $8.35 per share.
- Vesting: 25 % annually (fully vested after four years, per footnote 1).
- Expiration: 24 Jul 2035, giving a 10-year term after the first vesting date.
- Post-grant holdings: Filing shows 237,723 derivative securities held directly (includes the new option).
- Role: Ghoniem is marked as a Director; no change in status or control is indicated.
The transaction is classified under code “A” (grant) and represents routine director compensation rather than an open-market purchase or sale. No non-derivative share activity or cash proceeds are reported, and no other executives are listed. Financial performance metrics, earnings data, or guidance are not included in this filing.
Form 4 filing synopsis: Tecogen Inc. (TGEN) director Earl R. Lewis was granted 25,000 non-qualified stock options on 07/24/2025 at an exercise price of $8.35 per share. The award vests 25 % each year and carries a 10-year term, expiring 07/24/2035. No common shares were bought or sold and no cash changed hands at the time of grant.
After this transaction, Lewis holds 91,250 derivative securities (options) in total, all recorded as direct ownership. The filing represents routine equity compensation aimed at aligning the director’s incentives with long-term shareholder value. Because the transaction involves options rather than immediate share issuance, near-term cash flow and ownership percentages are unaffected; any dilution would occur only if the options are exercised in the future.
Tecogen Inc. (TGEN) Form 4: On 07/24/2025, director Angelina Galiteva was granted a non-qualified stock option for 25,000 shares of common stock at an exercise price of $8.35. The option vests 25 % annually and expires on 07/25/2035. No shares were sold or otherwise disposed of in this filing. Following the grant, Galiteva’s total derivative holdings stand at 225,000 option-linked shares. The filing, dated 07/28/2025, shows the transaction was made in a direct ownership capacity; there is no indication of indirect ownership or group filing. No non-derivative transactions were reported.
Tecogen (TGEN) filed an 8-K announcing governance and compensation changes dated 24 Jul 2025. The board has split the CEO and CFO/Treasurer roles; CEO Dr. Abinand Rangesh resigned as CFO/Treasurer and remains CEO & director. Roger P. Deschenes, CAO since Sept 2020 and former division CFO at L3, was appointed CFO, Principal Financial Officer and Treasurer while retaining his CAO duties, a move intended to strengthen internal controls.
Compensation adjustments: the committee raised Deschenes’ salary to $180k and granted equity worth ≈$200k (17,964 restricted shares plus 12,063 ISOs, 25 % annual vesting). Rangesh received ≈$600k in equity (53,892 RSAs, 24,075 ISOs, 12,048 NQ options). General Counsel John K. Whiting IV and VP Business Development Stephen Lafaille each received ≈$200k in equity and salary increases to $180k. All options are priced at the 24 Jul 2025 NYSE American close.
The board also authorized Dr. Rangesh to grant up to $200k in options to non-executive employees. A press release confirming Deschenes’ appointment was issued 28 Jul 2025 (Exhibit 99.1). No financial performance data were disclosed.
On 21 Jul 2025, Tecogen Inc. (TGEN) filed an 8-K announcing the closing of a firm-commitment underwritten public offering of 3,985,000 common shares (incl. 485,000 overallotment) at $5.00 per share. Gross proceeds equal roughly $19.9 million; after underwriting discounts and estimated expenses, net proceeds are about $18.16 million.
Roth Capital Partners served as sole manager and underwriter. Management intends to allocate the cash to product development, expanded sales & marketing, additional staffing, capital expenditures, and working capital as the company pursues entry into the data-center market. Exhibit 99.1 contains a related press release, furnished but not deemed filed under the Exchange Act.
FAQ
What is the current stock price of Tecogen (TGEN)?
What is the market cap of Tecogen (TGEN)?
